Substance abuse and movement disorders: Complex interactions and comorbidities

Current Drug Abuse Reviews

Volumn 5, Issue 3, 2012, Pages 243-253

  Deik, Andres ^a   Saunders Pullman, Rachel ^a,b   Luciano, Marta San ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alcohol; Chorea; Drugs; Dystonia; Movement disorders; Parkinsonism; Tics; Tremor

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; ANTIPARKINSON AGENT; ANTISTREPTOLYSIN; BENZODIAZEPINE; CAFFEINE; CANNABINOID; CARDIOLIPIN ANTIBODY; COCAINE; CYCLIC AMP; CYCLIC AMP BINDING PROTEIN; DEXTROMETHORPHAN; DIAMORPHINE; DILTIAZEM; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENTANYL; HOMOVANILLIC ACID; HYDROCODONE; LEVODOPA; METHCATHINONE; METHYLEPHEDRINE; OPIATE; PETHIDINE; PSEUDOEPHEDRINE; TETRAHYDROBIOPTERIN; TRAMADOL; UNINDEXED DRUG;

ADULT; ALCOHOL ABUSE; COMORBIDITY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DRUG DOSE TITRATION; ESSENTIAL TREMOR; HUMAN; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MYOCLONUS DYSTONIA; NEUROLOGICAL COMPLICATION; PARKINSON DISEASE; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE;

ALCOHOLISM; ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGENTS; HUMANS; MOVEMENT DISORDERS; PARKINSON DISEASE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84869098743     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205030243     Document Type: Review

References (162)

1. San Luciano M, Saunders-Pullman R. Substance abuse and movement disorders. Curr Drug Abuse Rev 2009; 2: 273-8.
2. Dennison U, Clarkson M, O'Mullane J, et al. The incidence and clinical correlates of lithium toxicity: a retrospective review. Ir J Med Sci 2011; 180: 661-5.
3. Cazzola M, Matera MG. Tremor and beta(2)-adrenergic agents: Is it a real clinical problem? Pulm Pharmacol Ther 2012; 25: 4-10.
4. Block F, Dafotakis M. [Drug-induced tremor]. Fortschr Neurol Psychiatr 2011; 79: 570-5.
5. Clark GT. Medical management of oral motor disorders: dystonia, dyskinesia and drug-induced dystonic extrapyramidal reactions. J Calif Dent Assoc 2006; 34: 657-67.
6. Cole C, Jones L, McVeigh J, et al. Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal 2011; 3: 89-96.
7. Behrman AD. Luck of the draw: common adulterants found in illicit drugs. J Emerg Nurs 2008; 34: 80-2.
8. Morgan JC, Sethi KD. Drug-induced tremors. Lancet Neurol 2005; 4: 866-76.
9. From the Centers for Disease Control and Prevention. Adverse events associated with ephedrine-containing products-Texas, December 1993-September 1995. JAMA 1996; 276: 1711-2.
10. Matsumoto T. [Understanding a new conception of addiction in current clinical practices]. Nihon Arukoru Yakubutsu Igakkai Zasshi 2012; 47: 13-23.
11. Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart Lung 1997; 26: 466-83; quiz 84-5.
12. Williams J, Pacula RL, Chaloupka FJ, et al. College students' use of cocaine. Subst Use Misuse 2006; 41: 489-509.
13. Matthews JC, Collins A. Interactions of cocaine and cocaine congeners with sodium channels. Biochem Pharmacol 1983; 32: 455-60.
14. Nakagawa T, Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N, N-diisopropyltryptamine (foxy). J Pharmacol Sci 2008; 106: 2-8.
15. Geracitano R, Federici M, Bernardi G, et al. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons. Ann N Y Acad Sci 2006; 1074: 320-9.
16. Buttner A. Review: The neuropathology of drug abuse. Neuropathol Appl Neurobiol 2011; 37: 118-34.
17. Bauer LO. Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients. Alcohol Clin Exp Res 1996; 20: 1196-201.
18. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985; 9: 469-77.
19. Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry 2011; 2: 64.
20. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J 2007; 83: 389-94.
21. Lason W. Neurochemical and pharmacological aspects of cocaineinduced seizures. Pol J Pharmacol 2001; 53: 57-60.
22. Kaye S, Darke S. Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. Addiction 2004; 99: 1315-22.
23. Bartzokis G, Beckson M, Lu PH, et al. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res 2000; 98: 93-102.
24. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements ('crack dancing'). Neurology 1994; 44: 751-2.
25. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990; 40: 999-1000.
26. Riday TT, Kosofsky BE, Malanga CJ. The rewarding and locomotor-sensitizing effects of repeated cocaine administration are distinct and separable in mice. Neuropharmacology 2011, 10.1016/j. neuropharm.2011.12.011
27. Steketee JD. Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol 2005; 17: 69-86.
28. Brown TE, Lee BR, Mu P, et al. A silent synapse-based mechanism for cocaine-induced locomotor sensitization. J Neurosci 2011; 31: 8163-74.
29. Duggal HS. Cocaine use as a risk factor for ziprasidone-induced acute dystonia. Gen Hosp Psychiatry 2007; 29: 278-9.
30. Hegarty AM, Lipton RB, Merriam AE, et al. Cocaine as a risk factor for acute dystonic reactions. Neurology 1991; 41: 1670-2.
31. Fines RE, Brady WJ, DeBehnke DJ. Cocaine-associated dystonic reaction. Am J Emerg Med 1997; 15: 513-5.
32. Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use. South Med J 1997; 90: 1050-2.
33. Scharf D. Opsoclonus-myoclonus following the intranasal usage of cocaine. J Neurol Neurosurg Psychiatry 1989; 52: 1447-8.
34. Brust JC. Substance abuse and movement disorders. Mov Disord 2010; 25: 2010-20.
35. Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry 1999; 45: 1630-5.
36. Kamath S, Bajaj N. Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord 2007; 22: 1190-1.
37. Beall CM, Strohl KP, Blangero J, et al. Ventilation and hypoxic ventilatory response of Tibetan and Aymara high altitude natives. Am J Phys Anthropol 1997; 104: 427-47.
38. Di Rocco A, Nasser S, Werner P. Inhaled cocaine used to relieve "off" periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases. J Clin Psychopharmacol 2006; 26: 689-90.
39. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
40. Mash DC, Ouyang Q, Pablo J, et al. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J Neurosci 2003; 23: 2564-71.
41. Mash DC, Adi N, Duque L, et al. Alpha synuclein protein levels are increased in serum from recently abstinent cocaine abusers. Drug Alcohol Depend 2008; 94: 246-50.
42. Callaghan RC, Cunningham JK, Sykes J, et al. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 2012; 120: 35-40.
43. Gray SD, Fatovich DM, McCoubrie DL, et al. Amphetaminerelated presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 2007; 186: 336-9.
44. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96: 678-85.
45. O'Suilleabhain P, Giller C. Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs. Mov Disord 2003; 18: 1378-81.
46. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med 1999; 340: 1443.
47. Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med 2003; 349: 96-7.
48. Kish SJ. What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? Mov Disord 2003; 18: 1219-23.
49. Jerome L, Doblin R, Mithoefer M. Ecstasy use-Parkinson's disease link tenuous. Mov Disord 2004; 19: 1386.
50. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005; 5: 79-86.
51. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335-40.
52. Vollenweider FX, Gamma A, Liechti M, et al. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241-51.
53. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273-7.
54. Priori A, Bertolasi L, Berardelli A, et al. Acute dystonic reaction to ecstasy. Mov Disord 1995; 10: 353.
55. Cosentino C. Ecstasy and acute dystonia. Mov Disord 2004; 19: 1386-7; author reply 7.
56. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin 2011; 29: 641-55.
57. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996; 19: 157-64.
58. Pilgrim JL, Gerostamoulos D, Woodford N, et al. Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int 2012; 215: 184-8.
59. Sikk K, Taba P, Haldre S, et al. Irreversible motor impairment in young addicts-ephedrone, manganism or both? Acta Neurol Scand 2007; 115: 385-9.
60. de Bie RM, Gladstone RM, Strafella AP, et al. Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol 2007; 64: 886-9.
61. Stepens A, Logina I, Liguts V, et al. A Parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008; 358: 1009-17.
62. Sikk K, Haldre S, Aquilonius SM, et al. Manganese-Induced Parkinsonism due to Ephedrone Abuse. Parkinsons Dis 2011; 2011: 865319.
63. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18: 8417-22.
64. Steidl S, Miller AD, Blaha CD, et al. M muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice. PLoS One 2011; 6: e27538.
65. Lauterbach EC. Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Clin Neuropharmacol 1999; 22: 87-92.
66. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 2006; 23: 229-35.
67. Isoardo G, Zibetti M, Troni W. Myoclonus of probable spinal origin as a potential side effect of tramadol. A case report. J Neurol 2005; 252: 852.
68. Cardoso F. Chorea: non-genetic causes. Curr Opin Neurol 2004; 17: 433-6.
69. Lussier D, Cruciani RA. Choreiform movements after a single dose of methadone. J Pain Symptom Manage 2003; 26: 688-91.
70. Adair JC, Gilmore RL. Meperidine neurotoxicity after organ transplantation. J Toxicol Clin Toxicol 1994; 32: 325-8.
71. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol 1981; 1: 319-21.
72. Kriegstein AR, Shungu DC, Millar WS, et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon"). Neurology 1999; 53: 1765-73.
73. Wolters EC, van Wijngaarden GK, Stam FC, et al. Leucoencephalopathy after inhaling "heroin" pyrolysate. Lancet 1982; 2: 1233-7.
74. Heales S, Crawley F, Rudge P. Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency. Mov Disord 2004; 19: 1248-51.
75. Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008; 63: 146-52.
76. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
77. Emborg ME. Nonhuman primate models of Parkinson's disease. ILAR J 2007; 48: 339-55.
78. Lee KW, Zhao X, Im JY, et al. Apoptosis Signal-Regulating Kinase 1 Mediates MPTP Toxicity and Regulates Glial Activation. PLoS One 2012; 7: e29935.
79. Matzler W, Nagele T, Gasser T, et al. Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology 2007; 68: 414.
80. Walters AS, Ondo WG, Zhu W, et al. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot postmortem study. J Neurol Sci 2009; 279: 62-5.
81. Budney AJ, Moore BA, Vandrey RG, et al. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112: 393-402.
82. Lozsadi DA, Forster A, Fletcher NA. Cannabis-induced propriospinal myoclonus. Mov Disord 2004; 19: 708-9.
83. Husseini L, Leussink VI, Warnke C, et al. [Cannabinoids for symptomatic therapy of multiple sclerosis.]. Nervenarzt 2012; 83: 695-704.
84. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40: 701-8.
85. Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459-65.
86. Muller-Vahl KR. Tourette's syndrome. Curr Top Behav Neurosci 2009; 1: 397-410.
87. Beckmann Y, Secil Y, Gungor B, et al. [Tardive dystonia and the use of cannabis]. Turk Psikiyatri Derg 2010; 21: 90-1.
88. Little JP, Villanueva EB, Klegeris A. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Rev Med Chem 2011; 11: 582-90.
89. Wadleigh A, Valenzuela CF. Ethanol increases GABAergic transmission and excitability in cerebellar molecular layer interneurons from GAD67-GFP knock-in mice. Alcohol Alcohol 2012; 47: 1-8.
90. Bhidayasiri R. Differential diagnosis of common tremor syndromes. Postgrad Med J 2005; 81: 756-62.
91. Kumar S, Singh RK, Goswami U, et al. A study of the temporal course of phenomenology of alcohol dependence. Am J Addict 2005; 14: 213-22.
92. Yokota O, Tsuchiya K, Terada S, et al. Alcoholic cerebellar degeneration: a clinicopathological study of six Japanese autopsy cases and proposed potential progression pattern in the cerebellar lesion. Neuropathology 2007; 27: 99-113.
93. Koller W, O'Hara R, Dorus W, et al. Tremor in chronic alcoholism. Neurology 1985; 35: 1660-2.
94. Gokula RM, Khasnis A. Asterixis. J Postgrad Med 2003; 49: 272-5.
95. Lopez W, Jeste DV. Movement disorders and substance abuse. Psychiatr Serv 1997; 48: 634-6.
96. Mellor CS, Jain VK. Diazepam withdrawal syndrome: its prolonged and changing nature. Can Med Assoc J 1982; 127: 1093-6.
97. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gammahydroxybutyrate withdrawal. Neurocrit Care 2008; 8: 430-3.
98. Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci 2007; 61: 207-8.
99. Hageman G, van der Hoek J, van Hout M, et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after longterm occupational solvent exposure. J Neurol 1999; 246: 198-206.
100. Goodheart RS, Dunne JW. Petrol sniffer's encephalopathy. A study of 25 patients. Med J Aust 1994; 160: 178-81.
101. McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 1981; 10: 290-7.
102. Mirsattari SM, Berry ME, Holden JK, et al. Paroxysmal dyskinesias in patients with HIV infection. Neurology 1999; 52: 109-14.
103. Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005; 4: 815-20.
104. Nahab FB, Peckham E, Hallett M. Essential tremor, deceptively simple. Pract Neurol 2007; 7: 222-33.
105. Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in essential tremor. Mov Disord 2001; 16: 914-20.
106. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord 2008; 23: 174-82.
107. Deuschl G, Bergman H. Pathophysiology of nonparkinsonian tremors. Mov Disord 2002; 17 Suppl 3: S41-8.
108. Louis ED, Faust PL, Ma KJ, et al. Torpedoes in the cerebellar vermis in essential tremor cases vs. controls. Cerebellum 2011; 10: 812-9.
109. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994; 35: 717-23.
110. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol 2006; 11: 117-25.
111. Zeuner KE, Molloy FM, Shoge RO, et al. Effect of ethanol on the central oscillator in essential tremor. Mov Disord 2003; 18: 1280-5.
112. Loewenstein Y. A possible role of olivary gap-junctions in the generation of physiological and pathological tremors. Mol Psychiatry 2002; 7: 129-31.
113. Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest 2005; 115: 774-9.
114. Harris RA, Trudell JR, Mihic SJ. Ethanol's molecular targets. Sci Signal 2008; 1: re7.
115. Mostile G, Jankovic J. Alcohol in essential tremor and other movement disorders. Mov Disord 2010; 25: 2274-84.
116. Schroeder D, Nasrallah HA. High alcoholism rate in patients with essential tremor. Am J Psychiatry 1982; 139: 1471-3.
117. Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand 1983; 68: 177-9.
118. Koller WC. Alcoholism in essential tremor. Neurology 1983; 33: 1074-6.
119. Ulmanova O, Vinopalova M, Zima T, et al. Biomarkers demonstrate increased consumption, but not abuse, of ethanol in essential tremor. J Neurol 2012; 259: 1177-80.
120. Nicoletti A, Mostile G, Cappellani R, et al. Wine drinking and essential tremor: a possible protective role. Mov Disord 2011; 26: 1310-5.
121. Nardocci N. Myoclonus-dystonia syndrome. Handb Clin Neurol 2011; 100: 563-75.
122. Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonusdystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489-92.
123. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 1999; 46: 794-8.
124. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996; 11: 119-24.
125. Raymond D, Ozelius L. Myoclonus-Dystonia [monograph on the internet]. Seattle (WA): Gene Reviews 1993. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20301587
126. Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005; 20: 1330-7.
127. Pueschel SM, Friedman JH, Shetty T. Myoclonic dystonia. Childs Nerv Syst 1992; 8: 61-6.
128. Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005; 11: 135-7.
129. Chadwick D, Hallett M, Harris R, et al. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977; 100: 455-87.
130. Marsden CD. Drug treatment of diseases characterized by abnormal movements. Proc R Soc Med 1973; 66: 871-3.
131. Trottenberg T, Meissner W, Kabus C, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonusdystonia syndrome. Mov Disord 2001; 16: 769-71.
132. Kuncel AM, Turner DA, Ozelius LJ, et al. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clin Neurol Neurosurg 2009; 111: 303-6.
133. Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004; 19: 724-7.
134. Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005; 76: 989-91.
135. Saunders-Pullman R, Shriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002; 58: 242-5.
136. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007; 68: 522-4.
137. Carbon M, Argyelan M, Eidelberg D. Functional imaging in hereditary dystonia. Eur J Neurol 2010; 17 Suppl 1: 58-64.
138. Yokoi F, Dang MT, Yang G, et al. Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models. Behav Brain Res 2012; 227: 12-20.
139. Gonthier B, Allibe N, Cottet-Rousselle C, et al. Specific Conditions for Resveratrol Neuroprotection against Ethanol-Induced Toxicity. J Toxicol 2012; 2012: 973134.
140. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-8.
141. Djamshidian A, Averbeck BB, Lees AJ, et al. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J Neurol Sci 2011; 310: 183-8.
142. Miyasaki JM, Al Hassan K, Lang AE, et al. Punding prevalence in Parkinson's disease. Mov Disord 2007; 22: 1179-81.
143. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20: 77-81.
144. Katzenschlager R. Dopaminergic dysregulation syndrome in Parkinson's disease. J Neurol Sci 2011; 310: 271-5.
145. Carter A, Hall W, Ambermoon P, et al. Stimulating debate in the field of addiction. Addiction 2012; 107: 253.
146. Ceravolo R, Frosini D, Rossi C, et al. Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J Neurol 2010; 257: S276-83.
147. Subramony JA. Apomorphine in dopaminergic therapy. Mol Pharm 2006; 3: 380-5.
148. Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a doseescalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007; 258: 137-43.
149. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease: a review. Expert Opin Pharmacother 2007; 8: 2799-809.
150. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
151. Tellez C, Bustamante ML, Toro P, et al. Addiction to apomorphine: a clinical case-centred discussion. Addiction 2006; 101: 1662-5.
152. Courty E, Durif F, Zenut M, et al. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 1997; 20: 140-7.
153. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997; 17: 1027-30.
154. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-8.
155. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111-27.
156. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132: 1376-85.
157. Brezovska K, Panovska AP, Grozdanova A, et al. Authors' reply. J Neurosci Rural Pract 2012; 3: 104-5.
158. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397-405.
159. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation Syndrome. PLoS One 2012; 7: e29768.
160. De la Casa-Fages B, Grandas F. Dopamine dysregulation syndrome and deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurol Res Int 2011; 2011: 759895.
161. Weintraub D, Mamikonyan E, Papay K, et al. Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale. Mov Disord 2011, 10.1002/mds.24023
162. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-70.